Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
CONCLUSIONS: In this post hoc analysis, niraparib efficacy was similar across PDS and NACT/IDS subgroups. Patients who had NACT/IDS and VRD had the highest reduction in the risk of progression with niraparib maintenance.PMID:35550709 | DOI:10.1016/j.ygyno.2022.04.012
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Roisin E O'Cearbhaill Jose-Alejandro P érez-Fidalgo Bradley J Monk Ignacio Tusquets Colleen McCormick Jose Fuentes Richard G Moore Christof Vulsteke Mark S Shahin Fr édéric Forget William H Bradley Sakari Hietanen David M O'Malley Anne D ørum Brian M Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Fallopian Tube Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | Study